This site is intended for healthcare professionals
A close up image of a microscope
  • Home
  • /
  • Clinical trials
  • /
  • Taltz
  • /
  • A Study in Participants With Moderate to Severe Ps...
Clinical trial

A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3)

Read time: 3 mins
Last updated:27th Jul 2012
Identifier: NCT01646177

This study will assess the safety and efficacy of ixekizumab (LY2439821), compared to etanercept and placebo in participants with moderate to severe chronic plaque psoriasis.


Study Type: Interventional  (Clinical Trial)
Actual Enrollment: 1346 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A 12-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients With Moderate to Severe Plaque Psoriasis With a Long-Term Extension Period
Actual Study Start Date: July 28, 2012
Actual Primary Completion Date: May 22, 2014
Estimated Study Completion Date: August 15, 2019

Arm:
- Placebo Comparator:
Placebo
- Active Comparator: 50 mg etanercept
- Experimental: 80 mg ixekizumab Dosing Regimen 2
- Experimental: 80 mg ixekizumab Dosing Regimen 1


Related journals:
- Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3).

- Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.

Category Value
Date last updated at source 2018-11-02
Study type(s) Interventional
Expected enrolment 1346
Study start date 2012-07-28
Estimated primary completion date 2014-05-22

View full details